Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy.
MetadataShow full item record
Endocrine therapy resistance invariably develops in advanced estrogen receptor-positive (ER+) breast cancer, but the underlying mechanisms are largely unknown. We have identified C-terminal SRC kinase (CSK) as a critical node in a previously unappreciated negative feedback loop that limits the efficacy of current ER-targeted therapies. Estrogen directly drives CSK expression in ER+ breast cancer. At low CSK levels, as is the case in patients with ER+ breast cancer resistant to endocrine therapy and with the poorest outcomes, the p21 protein-activated kinase 2 (PAK2) becomes activated and drives estrogen-independent growth. PAK2 overexpression is also associated with endocrine therapy resistance and worse clinical outcome, and the combination of a PAK2 inhibitor with an ER antagonist synergistically suppressed breast tumor growth. Clinical approaches to endocrine therapy-resistant breast cancer must overcome the loss of this estrogen-induced negative feedback loop that normally constrains the growth of ER+ tumors.
Version of record
Gene Expression Regulation, Enzymologic
Gene Expression Regulation, Neoplastic
License start date
Proc Natl Acad Sci U S A, 2018, 115 (31), pp. 7869 - 7878
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/
Showing items related by title, author, creator and subject.
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. Martin, L-A; Ribas, R; Simigdala, N; Schuster, E; Pancholi, S; Tenev, T; Gellert, P; Buluwela, L; Harrod, A; Thornhill, A; Nikitorowicz-Buniak, J; Bhamra, A; Turgeon, M-O; Poulogiannis, G; Gao, Q; Martins, V; Hills, M; Garcia-Murillas, I; Fribbens, C; Patani, N; Li, Z; Sikora, MJ; Turner, N; Zwart, W; Oesterreich, S; Carroll, J; Ali, S; Dowsett, M (2017-11-30)Resistance to endocrine therapy remains a major clinical problem in breast cancer. Genetic studies highlight the potential role of estrogen receptor-α (ESR1) mutations, which show increased prevalence in the metastatic, ...
Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial. Detre, SI; Ashley, S; Mohammed, K; Smith, IE; Powles, TJ; Dowsett, M (2017-03)The randomized, double-blinded Royal Marsden Tamoxifen Breast Cancer Prevention Trial in healthy high-risk women started in 1986 and is still blinded. Eligible participants (n = 2,471) were randomly assigned to tamoxifen ...
Dowsett, M; Johnston, S; Martin, LA; Salter, J; Hills, M; Detre, S; Gutierrez, MC; Mohsin, SK; Shou, J; Allred, DC; Schiff, R; Osborne, CK; Smith, I (2005-07)De novo resistance to endocrine therapy is a near-universal feature of oestrogen receptor (ER)- negative breast cancer. Although many ER-positive breast cancers also show no response to tamoxifen or aromatase inhibitors ...